Debt-laden Valeant faces tough choices in asset sales

NEW YORK (Reuters) – As Valeant Pharmaceuticals considers a multibillion-dollar auction to pare down $30 billion in debt, its challenge will be choosing which assets to sell without compromising any of its key businesses, analysts and investment bankers said.